NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives $11.67 Average PT from Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been given a consensus recommendation of “Hold” by the five analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $11.6667.

NMTC has been the subject of several research analyst reports. Weiss Ratings downgraded shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of NeuroOne Medical Technologies to a “sell” rating in a research report on Saturday, February 21st. JonesTrading started coverage on NeuroOne Medical Technologies in a research report on Monday, March 2nd. They issued a “buy” rating and a $9.00 target price for the company. Zacks Research downgraded NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 13th. Finally, LADENBURG THALM/SH SH increased their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th.

NeuroOne Medical Technologies Price Performance

Shares of NMTC stock opened at $3.24 on Wednesday. The firm has a 50 day moving average of $4.17 and a 200-day moving average of $4.46. The company has a market cap of $27.93 million, a price-to-earnings ratio of -3.81 and a beta of 0.51. NeuroOne Medical Technologies has a 52 week low of $3.11 and a 52 week high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The company had revenue of $1.86 million for the quarter, compared to analyst estimates of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 98.33%. Analysts anticipate that NeuroOne Medical Technologies will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On NeuroOne Medical Technologies

A number of institutional investors have recently modified their holdings of the company. Legato Capital Management LLC acquired a new stake in NeuroOne Medical Technologies in the 4th quarter valued at $34,000. Squarepoint Ops LLC acquired a new position in NeuroOne Medical Technologies during the fourth quarter worth $36,000. Susquehanna International Group LLP acquired a new position in NeuroOne Medical Technologies during the third quarter worth $47,000. XTX Topco Ltd bought a new position in shares of NeuroOne Medical Technologies in the second quarter valued at $51,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of NeuroOne Medical Technologies in the first quarter valued at $84,000. 16.07% of the stock is owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.